Evaluation of arterial stiffness and serum endocan levels in patients with primary aldosteronism with new-onset hypertension and long-term hypertension

Can, Mustafa; Kocabaş, Muhammet; Burgucu, H. Ç.; Yarar, Z.; Karadeniz, Y.; Karaköse, Melia; Yerlikaya, Fatma Hümeyra; Kulaksızoğlu, Mustafa; Karakurt, Feridun

doi:10.1007/s40618-022-01888-2

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, in a recent cross-sectional analysis, with 28 patients with primary aldosteronism (PA), a major cause of secondary HTN, 14 patients with primary HTN, and 28 healthy controls, it was demonstrated that circulating endocan levels were significantly lower in the PA group, compared to the other groups [ 59 ]. However, no other studies to date have assessed the correlation between endocan and secondary HTN.…”

Section: Endocan and Arterial Hypertensionmentioning

confidence: 99%

The Role of Endocan in Cardiometabolic Disorders

Klisić

Patoulias

2023

Metabolites

View full text Add to dashboard Cite

Discovered two decades ago, endocan still represents an intriguing biomarker related to inflammation. Endocan is a soluble dermatan sulphate proteoglycan secreted by endothelial cells. Its expression is observed in tissues related to the enhanced proliferation, especially hepatocytes, lungs, kidneys, etc. Endocan has been investigated in many cardiometabolic disorders that are tightly connected with inflammation, such as type 2 diabetes mellitus, hypertension, atherosclerotic cardiovascular disease, kidney disease, obesity, polycystic ovary syndrome, metabolic syndrome, non-alcoholic fatty liver disease, etc. In this narrative, comprehensive review of the currently available literature, special attention will be paid to the role of endocan in the broad spectrum of cardiometabolic disorders. Since endocan has emerged as a novel endothelial dysfunction marker, the discovery of potential therapeutic strategies for patients with certain cardiometabolic risk factors would be of great importance to delay or even prevent the onset and progression of related complications, mainly cardiovascular.

show abstract

Section: Endocan and Arterial Hypertensionmentioning

confidence: 99%